Printer Friendly

Eisai Files Application Seeking Additional Indication for ARICEPT in US.

Tokyo, Japan, Sept 3, 2005 - (JCNN) - Eisai announced on September 1 that its US subsidiary Eisai Medical Research has filed a supplemental New Drug Application (sNDA) for ARICEPT (donepezil HC1 tablet) with the U.S. Food and Drug Administration (FDA).

Eisai expects that ARICEPT will become applicable for the treatment of severe Alzheimer's disease. Currently, ARICEPT is available in 76 countries.

The company aims for ARICEPT sales of 185 billion yen ($1.7 bil) worldwide in fiscal 2005.

Source: JCN

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Sep 3, 2005
Previous Article:Asahi Kasei Chemicals Wins Orders for Membrane Bioreactor Wasterwater Treatment Plants in China.
Next Article:Takara Shuzo to Adopt Biodegradable Plastic Bottle Caps for Its Products.

Related Articles
Eisai Obtains Additional Approval for Its Thrombolytic Agent Cleactor Inj.
Eisai Announces Strategic Alliance With BioArctic Neuroscience To Develop Immunotherapy For Alzheimer's Disease.
Eisai Resubmits Supplemental New Drug Application for Aricept, Alzheimers Disease Drug, to FDA.
Eisai Announces Results of Overseas Clinical Trials of Donepezil in Treating Vascular Dementia.
Asahi Kasei Pharma and Eisai in Sales Promotion Agreement for Eril in China.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Eisai, Nitto Denko to Co-develop Transdermal Formulation of Alzheimer's Disease Agent ARICEPT.
Eisai Files Application Seeking Additional Indication for ARICEPT in Europe.
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP).
Eisai Announces Inovelon(R) Receives Marketing Authorization Approval from European Commission.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |